261 related articles for article (PubMed ID: 22123748)
21. The impact of IL2ra induction therapy in kidney transplantation using tacrolimus- and mycophenolate-based immunosuppression.
Gralla J; Wiseman AC
Transplantation; 2010 Sep; 90(6):639-44. PubMed ID: 20595929
[TBL] [Abstract][Full Text] [Related]
22. Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy.
Rivinius R; Helmschrott M; Ruhparwar A; Schmack B; Klein B; Erbel C; Gleissner CA; Akhavanpoor M; Frankenstein L; Darche FF; Thomas D; Ehlermann P; Bruckner T; Katus HA; Doesch AO
Drug Des Devel Ther; 2015; 9():93-102. PubMed ID: 25552900
[TBL] [Abstract][Full Text] [Related]
23. Post-transplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era.
Ciancio G; Siquijor AP; Burke GW; Roth D; Cirocco R; Esquenazi V; Byrne GE; Miller J
Clin Transplant; 1997 Jun; 11(3):243-9. PubMed ID: 9193850
[TBL] [Abstract][Full Text] [Related]
24. A retrospective analysis of dermatological lesions in kidney transplant patients.
Castello M; Gregorini M; Rampino T; Bosio F; Bedino G; Piotti G; Soccio G; Esposito P; Klersy C; Abelli M; Borroni G; Dal Canton A
Indian J Med Res; 2013 Jun; 137(6):1188-92. PubMed ID: 23852300
[TBL] [Abstract][Full Text] [Related]
25. Malignancy after renal transplantation in the new era of immunosuppression.
Watorek E; Boratynska M; Smolska D; Patrzalek D; Klinger M
Ann Transplant; 2011; 16(2):14-8. PubMed ID: 21716180
[TBL] [Abstract][Full Text] [Related]
26. Skin cancer after renal transplantation: Results of a multicenter study in Iran.
Einollahi B; Nemati E; Lessan-Pezeshki M; Simforoosh N; Nourbala MH; Rostami Z; Nafar M; Pourfarziani V; Beiraghdar F; Mahdavi-Mazdeh M; Ahmadpour P; Makhdoomi K; Ghafari A; Ardalan MR; Taebi Khosroshahi H; Oliaei F; Shahidi S; Makhlogh A; Azmandian J; Samimagham HR; Shabazian H
Ann Transplant; 2010; 15(3):44-50. PubMed ID: 20877266
[TBL] [Abstract][Full Text] [Related]
27. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients.
Wimmer CD; Angele MK; Schwarz B; Pratschke S; Rentsch M; Khandoga A; Guba M; Jauch KW; Bruns C; Graeb C
Transpl Int; 2013 Oct; 26(10):999-1006. PubMed ID: 23952102
[TBL] [Abstract][Full Text] [Related]
28. De novo malignancies in renal transplant recipients: experience at a single center with 1882 transplant patients over 39 yr.
Apel H; Walschburger-Zorn K; Häberle L; Wach S; Engehausen DG; Wullich B
Clin Transplant; 2013; 27(1):E30-6. PubMed ID: 23278453
[TBL] [Abstract][Full Text] [Related]
29. Effect of immunosuppression for primary renal disease on the risk of cancer in subsequent renal transplantation: a population-based retrospective cohort study.
Hibberd AD; Trevillian PR; Wlodarczyk JH; Kemp DG; Stein AM; Gillies AH; Heer MK; Sheil AG
Transplantation; 2013 Jan; 95(1):122-7. PubMed ID: 23238532
[TBL] [Abstract][Full Text] [Related]
30. Lack of Benefit and Potential Harm of Induction Therapy in Simultaneous Liver-Kidney Transplants.
AbdulRahim N; Anderson L; Kotla S; Liu H; Ariyamuthu VK; Ghanta M; MacConmara M; Tujios SR; Mufti A; Mohan S; Marrero JA; Vagefi PA; Tanriover B
Liver Transpl; 2019 Mar; 25(3):411-424. PubMed ID: 30506870
[TBL] [Abstract][Full Text] [Related]
31. Immunosuppressive Medications and Squamous Cell Skin Carcinoma: Nested Case-Control Study Within the Skin Cancer after Organ Transplant (SCOT) Cohort.
Coghill AE; Johnson LG; Berg D; Resler AJ; Leca N; Madeleine MM
Am J Transplant; 2016 Feb; 16(2):565-73. PubMed ID: 26824445
[TBL] [Abstract][Full Text] [Related]
32. Impact of induction immunosuppression on patient survival in heart transplant recipients treated with tacrolimus and mycophenolic acid in the current allocation era.
Amin AA; Araj FG; Ariyamuthu VK; Drazner MH; Ayvaci MUS; Mammen PPA; Mete M; Urey MA; Tanriover B
Clin Transplant; 2019 Aug; 33(8):e13651. PubMed ID: 31230375
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic features and outcome of mycophenolate-induced colitis in renal transplant recipients.
de Andrade LG; Rodrigues MA; Romeiro FG; Garcia PD; Contti MM; de Carvalho MF
Clin Transplant; 2014 Nov; 28(11):1244-8. PubMed ID: 25142167
[TBL] [Abstract][Full Text] [Related]
34. Posttransplant lymphoproliferative disorders in kidney transplant recipients: an Iranian multicenter experience.
Einollahi B; Lessan-Pezeshki M; Nourbala MH; Simforoosh N; Pourfarziani V; Nemati E; Nafar M; Basiri A; Pour-Reza-Gholi F; Firoozan A; Ghadiani MH; Makhdoomi K; Ghafari A; Ahmadpour P; Oliaei F; Ardalan MR; Makhlough A; Samimagham HR; Azmandian J; Razeghi E; Shahbazian H
Iran J Kidney Dis; 2008 Oct; 2(4):227-33. PubMed ID: 19377242
[TBL] [Abstract][Full Text] [Related]
35. De novo noncutaneous malignancies after kidney transplantation are associated with an increased risk of graft failure: results from a time-dependent analysis on 672 patients.
Cena T; Musetti C; Quaglia M; Magnani C; Stratta P; Bagnardi V; Cantaluppi V
Transpl Int; 2016 Oct; 29(10):1085-93. PubMed ID: 27343849
[TBL] [Abstract][Full Text] [Related]
36. Cancer risk with alemtuzumab following kidney transplantation.
Puttarajappa C; Yabes J; Bei L; Shah N; Bernardo J; McCauley J; Basu A; Tan H; Shapiro R; Unruh M; Wu C
Clin Transplant; 2013; 27(3):E264-71. PubMed ID: 23480032
[TBL] [Abstract][Full Text] [Related]
37. Three-year follow-up of malignancies in tacrolimus-treated renal recipients--an analysis of European multicentre studies.
Cowlrick I; Delventhal H; Kaipainen K; Krcmar C; Petan J; Schleibner S
Clin Transplant; 2008; 22(3):372-7. PubMed ID: 18279418
[TBL] [Abstract][Full Text] [Related]
38. Effect of mycophenolic acid and tacrolimus on the incidence of infectious complications after kidney transplantation.
Vnučák M; Graňák K; Skálová P; Laca Ľ; Mokáň M; Dedinská I
Int Immunopharmacol; 2021 Sep; 98():107908. PubMed ID: 34182244
[TBL] [Abstract][Full Text] [Related]
39. Postrenal transplant malignancy: Incidence, risk factors, and prognosis.
Elserwy NA; Lotfy EE; Fouda MA; Mahmoud MI; Donia AF; Mashaly ME; Abbas MH; Abuelmagd MM; Abouelenein RK; Ismail MI; Bakr MA
Saudi J Kidney Dis Transpl; 2017; 28(3):579-588. PubMed ID: 28540896
[TBL] [Abstract][Full Text] [Related]
40. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation.
O'Neill JO; Edwards LB; Taylor DO
J Heart Lung Transplant; 2006 Oct; 25(10):1186-91. PubMed ID: 17045930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
